# Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

> **NCT02456103** · PHASE3 · TERMINATED · sponsor: **PTC Therapeutics** · enrollment: 246 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT02456103
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-31
- **Primary completion:** 2017-06-02
- **Final completion:** 2017-06-02
- **Target enrollment:** 246 (ACTUAL)
- **Why stopped:** Cystic Fibrosis (CF) data from the double-blind CF Study PTC124-GD-021-CF did not meet endpoints.
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02456103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02456103, "Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02456103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*